Update: December 31st 2019
It was a very exciting year but in the end we could have just bought an index tracker. That would have saved me a lot of transaction costs. Only my broker got rich in the end of the year.
Auteur: the Wiseguy
Update: December 31st 2018
I made a few huge mistakes in the last month of the year. And all my profits vaporized in one month time. We call it learning money. Money you pay to learn from your mistakes.
What is SHOPIFY’S major task for the future?
One of my favorite stock for 2017 has to be Shopify (NYSE:SHOP). Since it’s IPO in may 2015 the stock has gone up 250% And rumor is that facebook and other big tech companies are looking to buy them. One of the biggest disadvantages for me is that they do…
Update: December 31st 2016
All in all a really nice return in the end. It’s been a rough ride but in the end payed of pretty nice.
Donald Trump America’s 45th President
Usually we do not discuss politics here but this time we will make an exception. America keeps amazing me. Every time they have to choose a president they never go for the save choice, that inspires me. After they had choosen the first black president in history, who performed exceptionally…
Estée Lauder – a steady climber in our longterm porto!
Since I have gotten my girlfriend involved in stock trading (and the fact that I believe that my porto will be a welcome addition to my pension later). We have tried to find some long term stocks that we both feel comfortable with. They say do not buy anything that…
GW’s Epidiolex results are worth mentioning
Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…
Porto Update 19-11-2015
Finally an update. These are my stock as per this month. So far it has not been a very good year. Most “winners” were already running last year and I have had to sell the worst “losers”. It was a really busy tent rental season so I didn’t have much…
OCAT – Q3 2015 – Results are in.
View: Annual Data | Quarterly Data All numbers in thousands Period Ending Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Total Revenue 84 39 39 39 Cost of Revenue 16 16 16 16 Gross Profit 69 24 24 24 Operating Expenses Research Development 4,336 3,544 3,378…